| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/25/2006 | EP0980427B1 Use of ulip proteins in the diagnosis and therapy of cancer and paraneoplastic neurological syndromes |
| 01/25/2006 | EP0914158B2 Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity |
| 01/25/2006 | EP0759781B1 Compositions for treating and preventing atherosclerosis |
| 01/25/2006 | CN1726211A Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase |
| 01/25/2006 | CN1726190A Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| 01/25/2006 | CN1726028A Solid drug for oral use |
| 01/25/2006 | CN1726023A Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| 01/25/2006 | CN1726022A Pregabalin derivatives for the treatment of fibromyalgia and other disorders and its derivitive |
| 01/25/2006 | CN1726014A Novel dry powder inhalation system for transpulmonary administration |
| 01/25/2006 | CN1724066A Controlled release composition and method of producing the same |
| 01/25/2006 | CN1724061A Traditional Chinese medicine prepn. for warming middle-jiao to dispel-cold and recuperating depleted yang and rescuing the patient from collapse, and its prepn. method |
| 01/25/2006 | CN1724023A Method for preparing Qingkailing |
| 01/25/2006 | CN1724008A Traditional Chinese medicine |
| 01/25/2006 | CN1723992A Method for preparing strengthening Yang eliminating fatigue granule, capsule and tables contg. nanometer pilose antler and micron powder of semen juglandis, pine potten and Taohualu ants etc. |
| 01/25/2006 | CN1723903A Matrix metalloproteinase and tumor necrosis factor inhibitors |
| 01/25/2006 | CN1238382C Molt-inhibiting hormone-1 protein of mitten crab |
| 01/25/2006 | CN1238376C Mutatant protein of human stem cell growth factor as well as its preparing method and medicine composition |
| 01/25/2006 | CN1238363C Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| 01/25/2006 | CN1238341C 1 Alpha-hydroxy-25-ene-vitamin D, analogs and use thereof |
| 01/25/2006 | CN1238041C Oral liquor for treating chronic fatigue syndrome |
| 01/25/2006 | CN1238024C Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method |
| 01/25/2006 | CN1237995C Drug for ripening and eliminating abnormal black balliary body fluid and its preparation method |
| 01/25/2006 | CN1237972C Active component of muskrat fragrant, preparing technique and usage |
| 01/25/2006 | CN1237968C Methods for inhibiting proliferation and inducing apoptosis of cancer cells |
| 01/25/2006 | CN1237957C Hypocrellin liposome solid powder preparaton and producing method |
| 01/25/2006 | CN1237905C Functional food capable of removing hydroxy free radical in body and its preparing method |
| 01/25/2006 | CN1237904C Health compound preserved gastrodia |
| 01/24/2006 | US6989452 Anticancer agents |
| 01/24/2006 | US6989401 Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products |
| 01/24/2006 | US6989398 Benzanilides as potassium channel openers |
| 01/24/2006 | US6989397 Iron chelators and uses thereof |
| 01/24/2006 | US6989396 Anticancer agents; modulating glycoprotein |
| 01/24/2006 | US6989395 TNF inhibitors |
| 01/24/2006 | US6989393 Ccr5 modulators benzimidazoles or benzotriazoles |
| 01/24/2006 | US6989388 Antitumor agents; anticancer agents; antiischemic agents; antiinflamamtory agents |
| 01/24/2006 | US6989385 Pyrazole compounds useful as protein kinase inhibitors |
| 01/24/2006 | US6989384 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 01/24/2006 | US6989383 Method of treating cancer |
| 01/24/2006 | US6989378 novel androgen (7 alpha ,17 beta )-7-methyl-17-[(1-oxoundecyl)oxy]estr-4en-3one); oil solubility; suitable for administration by means of injection; for male contraception |
| 01/24/2006 | US6989372 medicaments intended to increase the intracellular and/or extracellular level of glutathione (GSH); for example, N-(N-Acetyl-L-cysteinyl)-S-acetylcysteamine; hiv treatment |
| 01/24/2006 | US6989365 Methods of treatment with erythropoietin and albumin fusion protein |
| 01/24/2006 | US6989364 treatment extends to all stages of progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder |
| 01/24/2006 | US6989271 inducing differentiation via culturing stroma cells with serum, reducing agent (beta-mercaptoethanol), retinoic acid, and forskolin; for treatment of nervous system disorders |
| 01/24/2006 | US6989270 Using polyamide nucleic acid oligomers to engender a biological response |
| 01/24/2006 | US6989262 Plasmin variants and uses thereof |
| 01/24/2006 | US6989255 for protection against staphylococcus infection; fusion proteins |
| 01/24/2006 | US6989166 Soft drink replacer |
| 01/24/2006 | US6989156 Forming a free- standing powder comprising at least one antimicrobial metal with atomic disorder; and injecting the free-standing powder in therapeutically effective amounts to the tissue which is to be treated |
| 01/24/2006 | US6989146 Stress proteins and peptides and methods of use thereof |
| 01/24/2006 | CA2368431C Melanocortin receptor ligands |
| 01/24/2006 | CA2352392C Eletriptan hydrobromide monohydrate |
| 01/24/2006 | CA2347117C Methods for inhibiting diabetic complications |
| 01/24/2006 | CA2292984C Ccr5 modulators |
| 01/24/2006 | CA2261923C Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists |
| 01/24/2006 | CA2255824C Nitrate esters and their use for neurological conditions |
| 01/24/2006 | CA2166090C Novel process for preparing 17.beta.-substituted 4-azaandrostane derivatives |
| 01/24/2006 | CA2143419C Novel method for preparing ergothioneine |
| 01/19/2006 | WO2006006741A1 Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 01/19/2006 | WO2006006740A1 3-aminobenamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 01/19/2006 | WO2006006722A1 Method of controlling cell functions |
| 01/19/2006 | US20060015955 Alpha(1,3)Galactosyltransferase enzyme that assembles the Galalpha(1,3)Gal xenoantigen |
| 01/19/2006 | US20060014963 2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| 01/19/2006 | US20060014948 e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals |
| 01/19/2006 | US20060014835 Therapeutic agent for chronic obstructive pulmonary disease |
| 01/19/2006 | US20060014804 Cyanoguanidine prodrugs |
| 01/19/2006 | US20060014792 Heterocyclo inhibitors of potassium channel function |
| 01/19/2006 | US20060014788 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/19/2006 | US20060014787 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 01/19/2006 | US20060014780 Nicotinamide derivatives useful as PDE4 inhibitors |
| 01/19/2006 | US20060014774 1-allyl ergot alkaloid derivatives, methods for producing the same and the use thereof for preventing and treating migraine |
| 01/19/2006 | US20060014766 Reacting with sodium hydroxide then calcium chloride to form calcium salt derivative; 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors |
| 01/19/2006 | US20060014755 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 01/19/2006 | US20060014752 Heterocyclic anti-epileptogenic agents and methods of use thereof |
| 01/19/2006 | US20060014747 Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents |
| 01/19/2006 | US20060014746 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands |
| 01/19/2006 | US20060014742 Amide derivative |
| 01/19/2006 | US20060014730 Ansamycin formulations and methods for producing and using same |
| 01/19/2006 | US20060014725 6-(1-benzyl-3-pentyl-1H-indol-2-yl)-1-bromo-2-naphthyl 1H-tetraazol-5-ylmethyl ether; useful in treating stroke associated with or resulting from atrial fibrillation; thrombolytic agents for prohylaxis of cardiovascular disorders |
| 01/19/2006 | US20060014718 oversulfation of epiK-N sulfate to obtain an epiK5-amine-O-oversulfate with very high sulfation degree which by subsequent N-sulfation provides new epiK5-N,O-oversulfate-derivatives; free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field |
| 01/19/2006 | US20060014701 Novel amide derivatives as growth hormone secretagogues |
| 01/19/2006 | US20060014679 Drug screening; diabetes, obesity, hyperlipemia, arteriosclerosis, hypertension, cardiovascular disorders |
| 01/19/2006 | US20060014243 Human G-protein chemokine receptor HSATU68 |
| 01/19/2006 | US20060014242 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
| 01/19/2006 | US20060014180 Human phosphatase RET31, and variants thereof |
| 01/19/2006 | US20060013875 Combination immediate release controlled release levodopa/carbidopa dosage forms |
| 01/19/2006 | US20060013869 Electrospun amorphous pharmaceutical compositions |
| 01/19/2006 | US20060013860 Anticancer agents; side effect reduction |
| 01/19/2006 | US20060013852 Use of organic compounds |
| 01/19/2006 | US20060013829 Nucleic acid segments; coding zones; genetic engineered cells |
| 01/19/2006 | US20060013812 Mixture comprising blood coagulation factor and serpin for use in prevention and treatment of blood disorders |
| 01/19/2006 | US20060013775 Use of ppar activators for the treatment of pulmonary fibrosis |
| 01/19/2006 | CA2573611A1 Agent for promoting the recovery from dysfunction after the onset of central neurological disease |
| 01/19/2006 | CA2573609A1 Porphyrin derivatives and their use in photon activation therapy |
| 01/19/2006 | CA2573261A1 Compositions for enhancing the production of ppar and/or ppar-associated factors |
| 01/19/2006 | CA2561841A1 Methods for suppressing neovascularization using ephrinb2 |
| 01/18/2006 | EP1616957A1 Vector |
| 01/18/2006 | EP1616878A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/18/2006 | EP1616865A1 Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| 01/18/2006 | EP1616862A1 Nitrogenous heterocyclic compound and use thereof |
| 01/18/2006 | EP1616861A2 A process for the preparation of keto compounds |